Clinical trial design in hepatocellular carcinoma

Best Practice and Research: Clinical Gastroenterology

Volumn 19, Issue 1 SPEC. ISS., 2005, Pages 119-127

  Johnson, Philip J ^a   Billingham, Lucinda J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Hepatocellular carcinoma; Trial design

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOTOXIC AGENT; DOXORUBICIN; PLACEBO; PROTEIN P15; PROTEIN P16;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER TISSUE; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL DESIGN; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER RESECTION; LIVER TOXICITY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITATIVE ANALYSIS; RANDOMIZATION; REVIEW; TUMOR CELL; TUMOR VOLUME;

EID: 14744291298     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.11.004     Document Type: Review

References (36)

1. F. Macbeth R. Stephens R.P. Abratt et al. An open letter to all members of the IASLC Lung Cancer 45 2004 119-120
2. P. Therasse S.G. Arbuck E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 3 2000 204-216
3. T.W.T. Leung Y.Z. Patt W.Y. Lau et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1999 1676-1681
4. P.J. Johnson The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. In: A. Di Bisceglie (Ed.) Clinics in Liver Disease 2001 WB Saunders Philadelphia 145-159
5. Y. Sato K. Nakata Y. Kato et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein N Engl J Med 328 25 1993 1802-1806
6. T.C. Poon T.S. Mok A.T. Chan et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein Clin Chem 48 7 2002 1021-1027
7. I.H. Wong Y.M. Lo W. Yeo et al. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients Clin Cancer Res 6 2000 3516-3521
8. I.H.N. Wong Y.M.D. Lo J. Zhang et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients Cancer Res 59 1999 71-73
9. J.D. Wulfkuhle L.A. Liotta E.F. Petricoin Proteomic applications for the early detection of cancer Nat Rev Cancer 3 4 2003 267-275
10. T.C. Poon T.T. Yip A.T. Chan et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes Clin Chem 49 5 2003 752-760
11. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators Hepatology 28 1998 751-755
12. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire A new prognostic classification for predicting survival in patients with hepatocellular carcinoma J Hepatol 31 1 1999 133-141
13. X. Calvet J. Bruix P. Gines et al. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients Hepatology 12 1990 753-760
14. T.W. Leung A.M. Tang B. Zee et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients Cancer 94 6 2002 1760-1769
15. The new TNM classification in gastroenterology (1997) Endoscopy 30 7 1998 643-649
16. C.M. Lo H. Ngan W.K. Tso et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164-1171
17. J.M. Llovet M.I. Real X. Montana for the Barcelona Clinic Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial Lancet 359 2002 1734-1739
18. M.F. Yuen R.T. Poon C.L. Lai A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma Hepatology 36 3 2002 687-691
19. D. Machin M.J. Campbell Statistical tables for the design of clinical trials 1987 Blackwell Scientific Publications Oxford
20. R. Simon R. Wittes S. Ellenberg Randomised phase II clinical trials Cancer Treat Rep 69 1985 1375-1381
21. P-Y. Liu S. Dahlberg J. Crowley Selection designs for pilot studies based, on survival endpoints Biometrics 49 1993 391-398
22. J. Bruix M. Sherman J.M. Llovet et al. Clinical management of hepatocellular carcinoma J Hepatol 35 2001 421-430
23. M.L. Rothenberg M.J. Moore M.C. Cripps et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 1996 347-353
24. H.A. Burris M.J. Moore J. Andersen et al. Improvements in survival and clinical benefits with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 6 1997 2403-2413
25. C. Markham D.D. Stocken A.B. Hassan A phase II irinotecan-cisplatin combination in advanced pancreatic cancer Br J Cancer 89 2003 1860-1864
26. P. Lippe R.R. Silva L. Giuliodori et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients Anticancer Res 22 2002 1053-1059
27. J.F. Vansteenkiste J.E. Vandebroek K.L. Nackaerts et al. Clinical-benefit response in advanced non-small cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine Ann Oncol 12 2001 1221-1230
28. S. Petrasch A. Welt A. Reinacher et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer Br J Cancer 78 1998 511-514
29. S. Fields-Jones A. Koletsky G. Wilding et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial Ann Oncol 10 1999 1307-1310
30. J.M. Llovet J. Bruix for the Barcelona-Clinic Liver Cancer Group Systematic review of randomised trials for unresectable hepatocellular carcinoma: Chemoembolisation improves survival Hepatology 37 2003 429-442
31. R.G. Simonetti A. Liberati C. Angiolini L. Pagliaro Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials Ann Oncol 8 1997 117-136
32. C.L. Lai P.C. Wu G.C. Chan et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 1988 479-483
33. P.J. Johnson Are there indications for chemotherapy in hepatocellular carcinoma? Surg Oncol Clin N Am 12 1 2003 127-134
34. D. Schwartz J. Lellouch Explanatory and pragmatic attitudes in therapeutic trials J Chron Dis 20 1967 637-648
35. R.G. Gray D.J. Kerr C.C. McConkey et al. QUASAR: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial Lancet 355 2000 1588-1596
36. J.D. Schwartz M. Schwartz J. Mandeli M. Sung Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomised clinical trials Lancet Oncol 3 10 2002 593-603